MRI-informed active surveillance outcomes and dietary fibre acceptability: the Aberdeen experience

For many men diagnosed with early-stage prostate cancer, the immediate instinct is to seek a cure, often through surgery or radiation. However, a significant portion of these cancers grow so slowly that they may never cause harm during a man's lifetime. In these cases, doctors often recommend a strategy called active surveillance. Instead of treating the cancer right away, the medical team watches it closely with regular tests, stepping in with treatment only if the disease shows signs of becoming aggressive. This approach spares patients from the side effects of unnecessary treatment, but it requires a delicate balance: knowing exactly when to keep watching and when to intervene. To help make these decisions, doctors now use a specialized type of magnetic resonance imaging, or MRI, to look inside the prostate before deciding on a course of action. This technology assigns a score to any suspicious areas, helping to predict how likely a tumor is to cause trouble. The question remains, however, whether this new way of looking at the disease changes the timeline for when men stop watching and start treating, and whether men are willing to try simple lifestyle changes, like adding more fiber to their diet, to help manage their condition while they wait.

In a recent study conducted at Aberdeen Royal Infirmary, researchers looked back at the records of 420 men who were enrolled in an active surveillance program between 2012 and 2022. The team wanted to see how the introduction of an MRI-guided pathway affected the length of time men stayed on surveillance compared to an older method where men went straight to a biopsy. They also investigated whether the initial MRI scores could predict which men would need to stop surveillance sooner. Finally, they spoke with a small group of ten men to understand if they would be open to taking dietary fiber supplements as part of their care plan. The study found that the median follow-up period for these men was 3.1 years. Over the course of the study, nearly half of the participants, 208 men, decided to stop active surveillance for various reasons, with 176 of them stopping because their disease had progressed.

The timing of these decisions revealed a clear difference between the two groups. Men who entered the program through the MRI-informed pathway stopped surveillance sooner than those who started with the biopsy-first approach. The median time before stopping was 4.1 years for the MRI group, compared to 5.6 years for the biopsy group. The researchers noted that this difference was statistically significant, suggesting that the MRI pathway may have identified men who needed treatment earlier, or that the way patients were selected for the program had shifted. When the team looked closer at the MRI scores, they found that men who started with higher scores, indicating more concerning features in their scans, also stopped surveillance sooner. Among the men with recorded scores, those with higher-risk ratings stopped after a median of 2.9 years, while those with lower-risk ratings stayed on surveillance for a median of 4.0 years. This suggests that the initial scan results can help identify a specific group of men who are likely to need intervention sooner than others.

Beyond the clinical data, the researchers also explored the human side of living with a cancer that is being watched rather than treated. They interviewed ten men who were currently on active surveillance to gauge their feelings about adding dietary fiber to their daily routine. The men generally expressed a willingness to consider this type of supplementation, seeing it as a positive step they could take. However, they also voiced realistic concerns about potential side effects, such as digestive discomfort, and the hassle of following study procedures. The researchers concluded that while the idea of fiber supplementation is acceptable in principle, the practical burdens need to be managed carefully. The study ultimately highlights that while MRI technology helps refine who stays on surveillance and for how long, the experience of the patient remains central, with simple interventions like diet showing promise for future exploration.